Sanofi signed an R & D cooperation agreement with UCB worth nearly 140 million US dollars
-
Last Update: 2014-03-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley March 12, 2014 Sanofi recently announced that it has signed a research and development agreement with UCB, a Belgian biotechnology company, to develop new anti-inflammatory small molecule drugs, with a value of $138 million Sanofi hopes to consolidate its leading position in this field through this cooperation This agreement between Sanofi and UCB also extends the company's current plan to enhance its R & D and innovation capabilities through global cooperation In recent years, the R & D work of Sanofi company has been frustrated frequently, forcing the management of the company to reflect on the loopholes in its own R & D system On the other hand, UCB also hopes to accelerate the transformation of its R & D achievements through cooperation with Sanofi Ismail Kola, the company's chairman, said the cooperation will help the company to give full play to its innovation The agreement focuses on the research of inflammatory diseases such as rheumatoid arthritis Last year, the drug market reached $14 billion in sales.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.